A Randomized, Double-blind, Placebo-controlled Phase 2a Study of ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-Induced Mild Asthma (ARORAGE-2001)
Summary
This study is for patients with allergic asthma. Asthma can cause the airways of the lungs to narrow (airways are the tubes which carry air into the lungs). This can cause wheezing, shortness of breath, chest tightness and/or cough. This airway narrowing is often due to chronic inflammation in the lungs.
The investigational study drug (known as ARO-RAGE) is being developed to treat asthmatics by reducing the amount of a protein in the lung (called Receptor for Advanced Glycation End-products, or RAGE). The RAGE protein may cause inflammation in the lung airways, so it is possible that ARO-RAGE will decrease this inflammation. This may result in better airflow, improved symptoms, and fewer asthma flare-ups (exacerbations). It is also possible that you may receive no benefit and it may not result in these improved symptoms.
Eligibility
Eligible ages: 18 to 65
Accepts healthy participants: Yes
Inclusion criteria:
1. You are 18-65 years old
2. You have allergic asthma (your asthma flares up only with exposure to allergic triggers, such as animals or pollen).
Exclusion criteria:
1. You are pregnant, or plan to become pregnant.
2. You have significant health issues other than asthma.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Study coordinator, Curtis Dumonceaux
Principal investigator:
Richard Leigh
Clinical trial:
Yes
REB-ID:
REB25-1806